Moderna Therapeutics announced the launch of Valera LLC, a new Moderna venture focused exclusively on the advancement of vaccines and therapeutics for the prevention and treatment of viral, bacterial and parasitic infectious diseases. Valera will expand its team significantly in 2015 and will work out of Moderna's Venture Labs at 320 Bent Street, Cambridge, Mass.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
125.1 USD | +3.01% |
|
+7.81% | +25.83% |
07-15 | Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing | MT |
07-12 | China approves CSPC Pharma's RSV vaccine for clinical trials | RE |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B | |
-3.85% | 11.14B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna Therapeutics Launches New Venture Valera LLC for Infectious Diseases